Ingrid A.M. Mandjes

2.7k citations

37 papers · 1.2k indexed · h-index 16

Oncology top 5%
Cancer Research top 5%
Molecular Biology
Radiology, Nuclear Medicine and Imaging top 10%
Pulmonary and Respiratory Medicine

Co-authors: Jelle Wesseling Sabine C. Linn Gabe S. Sonke Erik van Werkhoven Inge Kemper Sjoerd Rodenhuis Mette S. van Ramshorst Jos H. Beijnen
Topics: HER2/EGFR in Cancer Research (18 papers)Cancer Treatment and Pharmacology (17 papers)Breast Cancer Treatment Studies (15 papers)
Cited by: Cancer Research Oncology Biomaterials
Journals: Journal of Clinical Oncology Cancer Research The Lancet Oncology
Partner nations: Netherlands Belgium Spain

In The Last Decade

Ingrid A.M. Mandjes

36 papers receiving 1.1k citations

Peers

Countries citing papers authored by Ingrid A.M. Mandjes

Since Specialization

Citations

This map shows the geographic impact of Ingrid A.M. Mandjes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid A.M. Mandjes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid A.M. Mandjes more than expected).

Fields of papers citing papers by Ingrid A.M. Mandjes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid A.M. Mandjes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid A.M. Mandjes. The network helps show where Ingrid A.M. Mandjes may publish in the future.

Co-authorship network of co-authors of Ingrid A.M. Mandjes

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid A.M. Mandjes. A scholar is included among the top collaborators of Ingrid A.M. Mandjes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid A.M. Mandjes. Ingrid A.M. Mandjes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs) 2024 ·Annals of Oncology ·Iris Nederlof,(unknown),(unknown),Gil Awada,(unknown),Hugo M. Horlings,Kristin Van de Vijver,Caroline A. Drukker,Frederieke van Duijnhoven,Marta López‐Yurda,Ingrid A.M. Mandjes,Ritse M. Mann,Claudette E. Loo,Christian U. Blank,Ton N. Schumacher,(unknown),(unknown)	3
2	Abstract OT2-15-01: COntinue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study 2023 ·Cancer Research ·(unknown),Tessa G. Steenbruggen,Ingrid A.M. Mandjes,Marta López‐Yurda,(unknown),T. Wiersma,Gabe S. Sonke	0
3	163MO Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial) 2023 ·Immuno-Oncology Technology ·Olga I. Isaeva,Iris Nederlof,(unknown),Bram Boeckx,(unknown),Ingrid A.M. Mandjes,Kristin Van de Vijver,(unknown),Caroline A. Drukker,(unknown),Gabe S. Sonke,(unknown),Christian U. Blank,Karin E. de Visser,(unknown),Lodewyk F.A. Wessels,Ton N. Schumacher,Hugo M. Horlings,Diether Lambrechts,Marleen Kok	1
4	Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial 2023 ·The Breast ·(unknown),Leonie Voorwerk,Sara Balduzzi,Roberto Salgado,Koen Van de Vijver,Marloes G. J. van Dongen,Inge Kemper,Ingrid A.M. Mandjes,(unknown),(unknown),John B.A.G. Haanen,Gabe S. Sonke,Hugo M. Horlings,Marleen Kok	15
5	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01) 2021 ·Breast Care ·(unknown),Ingrid A.M. Mandjes,Erik van Werkhoven,Harm van Tinteren,A. Elise van Leeuwen‐Stok,Petra M. Nederlof,Johanneke E.A. Portielje,Robbert J. van Alphen,(unknown),Daan van den Broek,Alwin D. R. Huitema,Marleen Kok,Sabine C. Linn,Hendrika M. Oosterkamp,(unknown)	6
6	90TiP Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial 2021 ·Annals of Oncology ·(unknown),Leonie Voorwerk,Karolina Sikorska,(unknown),Inge Kemper,Ingrid A.M. Mandjes,J.B.A.G. Haanen,Gabe S. Sonke,Marleen Kok	3
7	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial 2018 ·The Lancet Oncology ·Mette S. van Ramshorst,Anna van der Voort,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,Vincent O. Dezentjé,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,Agnès J. van de Wouw,Caroline M.P.W. Mandigers,Laurence J. van Warmerdam,Jelle Wesseling,Marie-Jeanne TFD Vrancken Peeters,Sabine C. Linn,Gabe S. Sonke	245
8	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) 2018 ·European Journal of Cancer ·(unknown),Marleen Kok,Erik van Werkhoven,Mark Opdam,Ingrid A.M. Mandjes,(unknown),Harm van Tinteren,Alexander L.T. Imholz,Johanneke E.A. Portielje,Monique M.E.M. Bos,Aart van Bochove,Jelle Wesseling,Emiel J. Rutgers,Sabine C. Linn,Hendrika M. Oosterkamp	10
9	Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial 2017 ·Annals of Oncology ·Marleen Kok,Hugo M. Horlings,(unknown),T. Wiersma,Nicola S. Russell,Leonie Voorwerk,Karolina Sikorska,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,(unknown),Sofie Wilgenhof,Myriam Chalabi,Jacqueline M. Stouthard,Gabe S. Sonke,Dana Cullen,Roberto Salgado,Ton N. Schumacher,Christian U. Blank,SC Linn	21
10	Selecting patients with oligo-metastatic breast cancer harboring homologous recombination deficiency (HRD) for intensified chemotherapy: The OLIGO-study 2017 ·Annals of Oncology ·Tessa G. Steenbruggen,Astrid N. Scholten,(unknown),Ingrid A.M. Mandjes,M. Holtkamp,Jelle Wesseling,SC Linn,Gabe S. Sonke	1
11	A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG 2012-03). 2017 ·Journal of Clinical Oncology ·Mette S. van Ramshorst,Erik van Werkhoven,Ingrid A.M. Mandjes,Inge Kemper,Vincent O. Dezentjé,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,(unknown),Caroline M.P.W. Mandigers,Jelle Wesseling,Marie‐Jeanne Vrancken Peeters,Sabine C. Linn,Gabe S. Sonke	5
12	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study 2017 ·European Journal of Cancer ·Mette S. van Ramshorst,Erik van Werkhoven,Ingrid A.M. Mandjes,Margaret Schot,Jelle Wesseling,Marie-Jeanne T.F.D. Vrancken Peeters,Jetske M. Meerum Terwogt,Monique E.M.M. Bos,Hendrika M. Oosterkamp,Sjoerd Rodenhuis,Sabine C. Linn,Gabe S. Sonke	18
13	The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure 2015 ·Breast Cancer Research and Treatment ·(unknown),Erik van Werkhoven,Ingrid A.M. Mandjes,Jelle Wesseling,Esther H. Lips,(unknown),Claudette E. Loo,Gabe S. Sonke,Sabine C. Linn,(unknown),Sjoerd Rodenhuis	3
14	Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer 2013 ·The Breast Journal ·Gabe S. Sonke,Ingrid A.M. Mandjes,M. Holtkamp,Margaret Schot,Erik van Werkhoven,Jelle Wesseling,Marie‐Jeanne Vrancken Peeters,Sjoerd Rodenhuis,Sabine C. Linn	11
15	Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics 2011 ·Breast Cancer Research and Treatment ·Esther H. Lips,Lennart Mulder,Jorma J. de Ronde,Ingrid A.M. Mandjes,Andrew Vincent,Marie-Jeanne T. F. D. Vrancken Peeters,Petra M. Nederlof,Jelle Wesseling,Sjoerd Rodenhuis	66
16	A simple system for grading the response of breast cancer to neoadjuvant chemotherapy 2009 ·Annals of Oncology ·Sjoerd Rodenhuis,Ingrid A.M. Mandjes,Jelle Wesseling,Marc J. van de Vijver,(unknown),Gabe S. Sonke,Sabine C. Linn	37
17	Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel 2001 ·Anti-Cancer Drugs ·Jetske M. Meerum Terwogt,W.W. ten Bokkel Huinink,Jan H.M. Schellens,Margaret Schot,Ingrid A.M. Mandjes,Maria Grazia Zurlo,(unknown),Hilde Rosing,Franciska J. Koopman,Jos H. Beijnen	192
18	PHARMACOLOGIC STUDY OF 3-HOUR 135 mg m−2PACLITAXEL IN PLATINUM PRETREATED PATIENTS WITH ADVANCED OVARIAN CANCER 1998 ·Pharmacological Research ·Vinodh R. Nannan Panday,Manon Huizing,L.J.C. van Warmerdam,R. Dubbelman,Ingrid A.M. Mandjes,Jan H.M. Schellens,W.W. ten Bokkel Huinink,Jos H. Beijnen	9
19	Toxicity grading systems 1994 ·Annals of Oncology ·(unknown),Giovanni Simonetti,Anne-Charlotte Dubbelman,W W ten Bokkel Huinink,Babs G. Taal,(unknown),Ingrid A.M. Mandjes,Otilia Dalesio,N.K. Aaronson	49
20	Autosomal dominant aniridia linked to the chromosome 11p13 markers catalase and D11S151 in a large Dutch family 1989 ·Cytogenetic and Genome Research ·M. Mannens,E. M. Bleeker‐Wagemakers,Jet Bliek,J.M.N. Hoovers,Ingrid A.M. Mandjes,Simon Tol,R.R. Frants,Christa Heyting,A. Westerveld,Rosalyn Slater	27

About Ingrid A.M. Mandjes

Ingrid A.M. Mandjes is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 37 papers that have together received 1.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (18 papers), Cancer Treatment and Pharmacology (17 papers) and Breast Cancer Treatment Studies (15 papers). The work is most often cited by research in Cancer Research (497 citations), Oncology (677 citations) and Biomaterials (146 citations). Ingrid A.M. Mandjes has collaborated with scholars based in Netherlands, Belgium and Spain. Frequent co-authors include Jelle Wesseling, Sabine C. Linn, Gabe S. Sonke, Erik van Werkhoven, Inge Kemper, Sjoerd Rodenhuis, Mette S. van Ramshorst, Jos H. Beijnen, W.W. ten Bokkel Huinink and Irma M. Oving. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact